IBIO301
Indication: Immuno-oncology
Target: LILRB1/2
Development Partner: Seeking
STAGE
Discovery
85%
Pre-Clinical
0%
Phase 1
0%
Phase 2
0%
IBIO401
Indication: Pediatric Leukemia
Target: HLA-Associated
Development Partner: Partnered, Undisclosed
STAGE
Discovery
85%
Pre-Clinical
0%
Phase 1
0%
Phase 2
0%
